Catalyst
Slingshot members are tracking this event:
Cellectar (CLRB) Initiates Fourth Cohort of Phase 1 Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma (rrMM)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLRB |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 22, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fourth Cohort, Phase 1, Clr-131, Relapsed/refractory Multiple Myeloma, Rrmm
